One approach to improve tolerability while maintaining efficacy has been to sequentially dose DDR inhibitors such as WEE1 inhibitors, which was shown to be feasible in ovarian cancer PDX models and on a recently reported Phase I trial [112, 113]. Here, WEE1 is linked to ovarian carcinoma.